Abstract
Hydroxychloroquine is used by 35% of SLE patients enrolled in the Baltimore Lupus Cohort. Eighty per cent of patients who took hydroxychloroquine at cohort entry remain on it six years later. In addition to its role for disease manifestations of lupus, hydroxychloroquine may be indicated for the prevention of disease or treatment-induced complications, including hyperlipidemia, diabetes mellitus, liver function test elevation and thrombosis.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antirheumatic Agents / therapeutic use*
-
Baltimore
-
Blood Glucose / metabolism
-
Cohort Studies
-
Diabetes Complications
-
Diabetes Mellitus / drug therapy
-
Female
-
Humans
-
Hydroxychloroquine / therapeutic use*
-
Hyperlipidemias / complications
-
Hyperlipidemias / drug therapy
-
Lipids / blood
-
Liver / physiopathology
-
Lupus Erythematosus, Systemic / complications
-
Lupus Erythematosus, Systemic / drug therapy*
-
Lupus Erythematosus, Systemic / physiopathology
-
Male
-
Thrombosis / complications
-
Thrombosis / drug therapy
-
Thrombosis / prevention & control
Substances
-
Antirheumatic Agents
-
Blood Glucose
-
Lipids
-
Hydroxychloroquine